Last CNY10.00 CNY
Change Today +0.13 / 1.32%
Volume 2.4M
002365 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

qianjiang yongan pharm-a (002365) Snapshot

Open
CNY9.83
Previous Close
CNY9.87
Day High
CNY10.04
Day Low
CNY9.80
52 Week High
02/25/14 - CNY10.90
52 Week Low
11/8/13 - CNY8.10
Market Cap
1.9B
Average Volume 10 Days
3.3M
EPS TTM
CNY0.08
Shares Outstanding
187.0M
EX-Date
06/13/14
P/E TM
129.7x
Dividend
CNY0.03
Dividend Yield
0.30%
Current Stock Chart for QIANJIANG YONGAN PHARM-A (002365)

Related News

No related news articles were found.

qianjiang yongan pharm-a (002365) Related Businessweek News

No Related Businessweek News Found

qianjiang yongan pharm-a (002365) Details

Qianjiang Yongan Pharmaceutical Co., Ltd. engages in the production and distribution of taurine products in China and internationally. Its taurine products are primarily applied in nutrition and health products, food additives, and other areas. The company was founded in 2001 and is based in Qianjiang, China.

Founded in 2001

qianjiang yongan pharm-a (002365) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

qianjiang yongan pharm-a (002365) Key Developments

Qianjiang Yongan Pharmaceutical Co., Ltd. to Report Q1, 2014 Results on Apr 26, 2014

Qianjiang Yongan Pharmaceutical Co., Ltd. announced that they will report Q1, 2014 results on Apr 26, 2014

Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year 2013

Qianjiang Yongan Pharmaceutical Co., Ltd. proposes cash dividend of CNY 0.30000000 per 10 shares (tax included) for the year 2013 to the Annual General Meeting to be held on April 21, 2014.

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2014

Qianjiang Yongan Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2014., at 09:30 China Standard Time. Agenda: To consider 2013 work report of the board of directors; to consider 2013 work report of the supervisory committee; to consider annual report and its summary; to consider 2013 financial resolution report; to consider profit distribution plan; to consider reappointment of audit firm; to consider special report on storage and use of raised funds in 2013; and to consider by-election of directors, including Wu Yuxi.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002365:CH CNY10.00 CNY +0.13

002365 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002365.
View Industry Companies
 

Industry Analysis

002365

Industry Average

Valuation 002365 Industry Range
Price/Earnings 100.0x
Price/Sales 3.5x
Price/Book 1.7x
Price/Cash Flow 129.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIANJIANG YONGAN PHARM-A, please visit www.chinataurine.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.